Immune dysregulation in atopic dermatitis

被引:51
作者
del Giudice, Michele Miraglia
Decimo, Fabio
Leonardi, Salvatore
Maioello, Nunzia
Amelio, Raffaele
Capasso, Antonella
Capristo, Carlo
Capristo, Angelo F.
机构
[1] Univ Naples 2, Dept Pediat, Naples, Italy
[2] Univ Catania, Dept Pediat, Catania, Italy
关键词
D O I
10.2500/aap.2006.27.2887
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
Atopic dermatitis (AD) is a chronic, relapsing, highly pruritic, inflammatory skin disease characterized by cutaneous hyperreactivity to environmentals triggers. Recent data suggest the presence of two different forms of AD: an extrinsic AD with elevated IgE involving 70-80% of the patients and an intrinsic AD with serum IgE not elevated and no specific IgE. Patients with extrinsic AD have elevated Th2- and decreased Th1-expressing cells in the peripheral blood, with elevated IL-4 and IL-13 expression, as well as IL-5. On the contrary, the intrinsic AD is linked with much lower levels of IL-4 and IL-13. Genetic factors are involved in the control of the disease and in the intrinsic AD the same chromosomal regions seem to be associated with psoriasis susceptibility. The AD is characterized by a complex of immunological alterations involving interactions between IgE-bearing antigen-presenting cells, T-cell activation, mast-cell degranulation, keratinocytes, eosinophils, and a combination of immediate and cellular immune responses. Inflammatory dendritic epidermal cells constitute a distinct dendritic cells population that is mainly found in AD and could induce the Th2/Th1 isotopic switch contributing to AD chronic phase. Therapy is based on interventation in the pathophysiology of atopic eczema and elimination of exogenous provocation factors.
引用
收藏
页码:451 / 455
页数:5
相关论文
共 37 条
[1]   The role of topical calcineurin inhibitors in atopic dermatitis [J].
Alomar, A ;
Berth-Jones, J ;
Bos, JD ;
Giannetti, A ;
Reitamo, S ;
Ruzicka, T ;
Stalder, JF ;
Thestrup-Pedersen, K .
BRITISH JOURNAL OF DERMATOLOGY, 2004, 151 :3-27
[2]   Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials [J].
Ashcroft, DM ;
Dimmock, P ;
Garside, R ;
Stein, K ;
Williams, HC .
BMJ-BRITISH MEDICAL JOURNAL, 2005, 330 (7490) :516-522
[3]   Association and linkage of atopic dermatitis with chromosome 13q12-14 and 5q31-33 markers [J].
Beyer, K ;
Nickel, R ;
Freidhoff, L ;
Björkstén, B ;
Huang, SK ;
Barnes, KC ;
MacDonald, S ;
Forster, J ;
Zepp, F ;
Wahn, V ;
Beaty, TH ;
Marsh, DG ;
Wahn, U .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (05) :906-908
[4]  
Blauvelt Andrew, 2003, Journal of Allergy and Clinical Immunology, V111, pS560
[5]   The genetics of psoriasis, psoriatic arthritis and atopic dermatitis [J].
Bowcock, AM ;
Cookson, WOCM .
HUMAN MOLECULAR GENETICS, 2004, 13 :R43-R55
[6]   Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: Changes in barrier function provide a sensitive indicator of disease activity [J].
Chamlin, SL ;
Kao, J ;
Frieden, IJ ;
Sheu, MY ;
Fowler, AJ ;
Fluhr, JW ;
Williams, ML ;
Elias, PM .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2002, 47 (02) :198-208
[7]   Asthma genetics [J].
Cookson, WOC .
CHEST, 2002, 121 (03) :7S-13S
[8]  
Eichenfield Lawrence F, 2003, J Am Acad Dermatol, V49, P1088, DOI 10.1016/S0190-9622(03)02539-8
[9]   Consensus guidelines in diagnosis and treatment of atopic dermatitis [J].
Eichenfield, LF .
ALLERGY, 2004, 59 :86-92
[10]   International Consensus Conference on Atopic Dermatitis II (ICCAD II): clinical update and current treatment strategies [J].
Ellis, C ;
Luger, T ;
Abeck, D ;
Allen, R ;
Graham-Brown, RAC ;
De Prost, Y ;
Eichenfield, LF ;
Ferrandiz, C ;
Giannetti, A ;
Hanifin, J ;
Koo, JYM ;
Leung, D ;
Lynde, C ;
Ring, J ;
Ruiz-Maldonado, R .
BRITISH JOURNAL OF DERMATOLOGY, 2003, 148 :3-10